QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision medicine
May 29 2024 - 4:05PM
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced
the launch of its QIAseq Multimodal DNA/RNA Lib Kit. The new kit
enables seamless preparation of DNA and RNA libraries for
next-generation sequencing (NGS), such as whole genome sequencing
(WGS) and whole transcriptome sequencing (WTS), as well as
downstream target enrichment based on hybrid-capture from a single
sample.
The QIAseq Multimodal DNA/RNA Lib Kit
facilitates multiomics, the studies of several omic fields like
genomics, transcriptomics and proteomics, aiming to gain a deeper
understanding of biological processes and systems – something
crucial for studying diseases like cancer. The kit offers a
streamlined and rapid workflow to generate WGS and WTS libraries
from a single sample by combining chemistry optimized for DNA and
RNA simultaneously. Using traditional methods, separate workflows
for DNA and RNA sequencing require a large amount of sample
material, labor-intensive library preparation procedures, and long
turn-around times.
“With the introduction of the QIAseq Multimodal
DNA/RNA Lib Kit, we are addressing a direct need in the scientific
community for a more efficient way to conduct multiomic studies,”
said Nitin Sood, Senior Vice President, Head of the Life Sciences
Business Area at QIAGEN. “Studying and understanding the complexity
of biological systems better will facilitate identifying potential
biomarkers for diseases or therapeutic targets for drug development
and finally advance precision medicine and healthcare.”
Researchers can also use the QIAseq Multimodal
DNA/RNA Lib Kit for generating DNA-only or RNA-only libraries. It
is the first NGS multimodal kit on the market that is compatible
with a wide range of input samples, including blood, Formalin-Fixed
Paraffin-Embedded (FFPE) samples, and cell-free DNA (cfDNA). This
is particularly relevant in translational research, such as in the
study of cancers, where different types of samples may be
available. The kit is highly sensitive, enabling detection of both
DNA and RNA rare variants. The DNA and RNA libraries generated
using the QIAseq Multimodal DNA/RNA Lib Kit are directly compatible
with different sequencing platforms such as Illumina instruments
and Element Aviti and can be sequenced on other sequencers with an
added conversion step (Complete Genomics/MGI, Singular Genomics,
and Ultima Genomics).
Additionally, the flexibility of generating DNA
only or RNA only libraries, as well as DNA and RNA libraries
compatible with further target enrichment by hybrid capture,
consolidates an NGS lab’s multiple workflows into a single kit,
saving lab resources while enhancing efficiency. For target
enrichment, the QIAseq xHYB Human panels can be used for WES (Whole
Exome Sequencing), or targeted sequencing with custom designed
content. The libraries are also compatible with hybrid capture
panels from other providers.
The new kit adds to QIAGEN's growing portfolio
that harnesses the true potential of NGS in biological research by
offering fast and efficient solutions that reduce turnaround times
and maximize sequencing capacity. With a focus on front-end sample
processing and downstream bioinformatics, QIAGEN provides
innovative NGS technologies for genomics, transcriptomics,
epigenomics, and metagenomics applications.
QIAGEN’s QIAseq kits have processed over four
million NGS samples, enabling biomarker research, gene expression
studies, viral epidemiology, and disease surveillance. From DNA and
RNA sequencing to multimodal sequencing and epigenomics, the
comprehensive range of QIAseq kits delivers reliable data on any
sequencing instruments.
More information about QIAGEN’s genomics
offering can be found here:
https://www.qiagen.com/us/applications/next-generation-sequencing.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare) and Life Sciences (academia, pharma
R&D and industrial applications, primarily forensics). As of
March 31, 2024, QIAGEN employed more than 5,900 people in over
35 locations worldwide. Further information can be found at
https://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, timing for launch
and development, marketing and/or regulatory approvals, financial
and operational outlook, growth and expansion, collaborations,
markets, strategy or operating results, including without
limitation its expected adjusted net sales and adjusted diluted
earnings results, are forward-looking, such statements are based on
current expectations and assumptions that involve a number of
uncertainties and risks. Such uncertainties and risks include, but
are not limited to, risks associated with management of growth and
international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, and its
impact on the demand for our products and other aspects of our
business, or other force majeure events; as well as the possibility
that expected benefits related to recent or pending acquisitions
may not materialize as expected; and the other factors discussed
under the heading “Risk Factors” contained in Item 3 of our most
recent Annual Report on Form 20-F. For further information, please
refer to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.Category: Corporate
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Domenica Martorana
QIAGEN N.V.
+49 210 29 11244
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
pr@qiagen.com
Lisa Mannagottera
QIAGEN N.V.
+49 2103 29 14181
pr@qiagen.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024